Docoh
Loading...

PHAS PhaseBio Pharmaceuticals

APP
Utility
Methods and Compositions for Treating Cystic Fibrosis
27 Jan 22
The present disclosure provides a method of treating diseases or disorders associated with CFTR protein dysfunction, including Cystic Fibrosis, by administering stable, long-lasting vasoactive intestinal peptide therapeutic agents.
Susan ARNOLD, David James BALLANCE
Filed: 1 Jul 21
APP
Utility
Metalloenzyme Inhibitor Compounds
13 Jan 22
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
Steven SPARKS, Christopher M. YATES, Sammy R. SHAVER
Filed: 31 Aug 21
APP
Utility
Methods of Reversing Ticagrelor Activity
11 Nov 21
The present disclosure provides a method of reversing ticagrelor-associated bleeding in a patient by administering an antibody or fragment thereof that binds to ticagrelor.
John LEE, David James BALLANCE
Filed: 20 Sep 19
APP
Utility
Metalloenzyme Inhibitor Compounds
21 Oct 21
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
Steven SPARKS, Christopher M. YATES, Sammy R. SHAVER, William J. HOEKSTRA
Filed: 17 Jun 21
GRANT
Utility
Metalloenzyme inhibitor compounds
5 Oct 21
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
Steven Sparks, Christopher M. Yates, Sammy R. Shaver
Filed: 17 Jan 20
GRANT
Utility
Methods and compositions for treating cystic fibrosis
6 Jul 21
The present disclosure provides a method of treating diseases or disorders associated with CFTR protein dysfunction, including Cystic Fibrosis, by administering stable, long-lasting vasoactive intestinal peptide therapeutic agents.
Susan Arnold, David James Ballance
Filed: 8 May 15
GRANT
Utility
Metalloenzyme inhibitor compounds
22 Jun 21
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
Steven Sparks, Christopher M. Yates, Sammy R. Shaver, William J. Hoekstra
Filed: 7 Sep 18
APP
Utility
Methods and Compositions for Treating Muscle Disease and Disorders
11 Mar 21
The present disclosure provides a method of treating muscle myopathy, including muscle dystrophies and cardiomyopathies, by administering stable, long-lasting vasoactive intestinal peptide therapeutic agents.
Lynne GEORGOPOULOS, Susan ARNOLD, David James BALLANCE
Filed: 22 Jun 20
GRANT
Utility
Use of modified vasoactive intestinal peptides in the treatment of hypertension
9 Mar 21
The present invention is based on the discovery that a VIP having a binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies.
Lynne M. Georgopoulos, Susan Arnold
Filed: 26 Sep 16
APP
Utility
Metalloenzyme Inhibitor Compounds
16 Dec 20
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
Steven Sparks, Christopher M. Yates, Sammy R. Shaver
Filed: 16 Jan 20
APP
Utility
Elp Fusion Proteins for Controlled and Sustained Release
11 Nov 20
The present disclosure provides pharmaceutical formulations for sustained release, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations.
James JOWETT, David James BALLANCE
Filed: 26 Jul 20
GRANT
Utility
ELP fusion proteins for controlled and sustained release
27 Jul 20
The present disclosure provides pharmaceutical formulations for sustained release, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations.
James Jowett, David James Ballance
Filed: 19 Nov 15
GRANT
Utility
Methods and compositions for treating muscle disease and disorders
22 Jun 20
The present disclosure provides a method of treating muscle myopathy, including muscle dystrophies and cardiomyopathies, by administering stable, long-lasting vasoactive intestinal peptide therapeutic agents.
Lynne Georgopoulos, Susan Arnold, David James Ballance
Filed: 8 Feb 16
  • 1
Patents are sorted by USPTO publication date, most recent first